What's in Lars Wiuff Andersen's pipeline?

Lars Wiuff Andersen has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Lars Wiuff Andersen's portfolio?

Top competitors by shared drug class: University of Sao Paulo.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lars-wiuff-andersen.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Lars Wiuff Andersen — Portfolio Competitive Intelligence Brief

Lars Wiuff Andersen pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Vasopressin, Arginine	Vasopressin, Arginine	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptors (V1a, V1b, V2)	Cardiovascular; Endocrinology; Hemostasis

Therapeutic area mix

Cardiovascular; Endocrinology; Hemostasis · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

University of Sao Paulo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lars Wiuff Andersen:

Cite this brief

Drug Landscape (2026). Lars Wiuff Andersen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lars-wiuff-andersen. Accessed 2026-05-14.